Company
About us
History
Leaderships
Team
EU grants
Requests for Proposal
Sustainability – ESG
Bussines strategy
Quality policy
Virtual Tour
Investors
Corporate documents
Shareholders and shares
Periodic reports
Current reports
Sustainability reports
Corporate governance at Mabion
Financial data
For Investors
Calendar
Resources
Science Hub
Press releases
News
Events
Media kit
Services
Process Development
Analytics
Drug Substance Manufacturing
Contact
Contact form
Contact for investors
Contact for media
Careers
Science News
Resources
Vaccines
Innovative Biologics Expected Approvals in 2026
Antibody-drug conjugates
,
Biologics
,
Bispecific antibody
,
Clinical trials
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
Monoclonal Antibody Prophylaxis for Infectious Diseases – Passive Immunization and Prevention
Monoclonal antibody
,
Vaccines
Mammalian Cell Lines as a Platform for Protein Vaccine Production
Cell culture
,
Drug substance
,
Manufacturing
,
Proteins
,
Vaccines
Innovative Biologics – Expected Drug Approvals in 2025
Antibody-drug conjugates
,
Biologics
,
Bispecific antibody
,
Clinical trials
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
A synergy of excellence: Novavax-Mabion partnership on vaccine during unprecedented times amid the COVID-19 pandemic
Mabion
,
Vaccines
Top 10 biologics approved in 2023
Biologics
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
Latest trends in the prevention and treatment of cervical cancer
Cancer
,
Vaccines
